医药魔方 / 最新资讯 / 正文

诺和诺德中国创新开放平台INNOVO启动,这家制药巨头想找什么样的合作伙伴?

医药魔方 医药魔方 来源:医药魔方
2019-03-09
诺和诺德
原文

3月6日,诺和诺德中国研发中心在京宣布启动INNOVO创新开放平台,旨在通过开放式的创新合作模式,携手中国本土的生物医药创新力量,共同搭建医药创新研发合作新生态,加快科研成果向创新药物研发的转化。

2019年是诺和诺德在中国开展经营业务的25周年,选择此时启动一个创新开放平台,体现了诺和诺德创新模式的升级以及对中国市场的重视。医药魔方记者受邀参加了此次的INNOVO开放创新平台启动仪式,在此为大家分享一些关于INNOVO平台合作运营模式以及诺和诺德全球研发策略的信息。


INNOVO是什么?


随着国家“创新驱动发展”战略的深入实施,以及中国医药产业的创新实力不断提高,中国已经成为全球最活跃的医药市场之一。从政策层面上看,最近几年中国药监机构的审批效率明显提升,新药投资退出、医保支付、市场准入的路径也在不断疏通,这给中国医药产业的发展注入了活力。在早前一批创新药企业开始步入收获期陆续有创新药被批准上市的同时,更多优秀的创业者与初创企业还在源源不断涌现。

 

中国“一片大好”的医药产业发展势头自然吸引了全球的目光,这一点仅从中国企业在创新药领域的跨境合作上已成常态上便能感受得到。作为扎根中国市场多年的老牌制药巨头之一,诺和诺德较早便在中国成立了研发中心,而此次由诺和诺德中国研发中心发起的INNOVO实际上是一个开放式的创新开放平台,相当于是诺和诺德在研发模式上的革新,标志着诺和诺德从此前更多专注于内部研发到愿意以更开放的姿态与全产业合作。

诺和诺德全球药物开发部高级副总裁 Marcus Schindler在接受记者采访时表示:“诺和诺德的核心贡献是为患者不断创新研发更好的药品。我们为寻找下一代药物进行长期的创新投入,不断提升覆盖完整价值链的研发能力,并通过外部合作进行强化和补充,将科学创想转化为切实的患者获益。我们期望INNOVO的开放式创新模式能够更高效地提升创新药物研发效率,满足患者未被满足的医疗需求。”

 

Marcus Schindler对INNOVO平台的运营也是充满了期待:“我们必须从全球的角度去吸引更多的外部创新,从而和各个合作伙伴建立非常紧密的合作关系,得到好的想法和好的技术,帮助我们进行科学的转化。我们不管这些点子和技术来自何方,只要能够为患者带来实实在在的利益,我们就考虑跟他们进行深入地合作。而且我们在遴选这些点子方面积累了丰富的经验,我们也可以把这些想法和技术变成真正能造福患者的产品。因此,我们认为诺和诺德INNOVO开放创新平台将会是整个公司第一个真正能够系统性地和外部合作伙伴共同合作的平台。在这个平台上我们将会邀请大量科学家共同加入。”


诺和诺德想找什么样的合作伙伴?


近年来,部分医药企业积极探索和实践开放式创新。比如强生2017年12月落户张江的JLABS复制其全球开放式创新平台的运作模式,计划容纳近50 家生命科学与医疗健康领域创新实体,吸引独立创业者或出初具规模的创业公司与其合作。国内企业中,贝达药业的梦工厂也可以说是同样的思路。

 

INNOVO有自己的独特之处。一方面,诺和诺德自身在糖尿病、血友病等领域有较为深厚的积累,而且是最早在中国成立研发中心的跨国生物制药企业。在INNOVO开放创新平台的运营中,诺和诺德中国研发中心期望凭借对疾病和患者情况的深入理解、实力雄厚的临床前及临床实验平台、治疗性蛋白质和多肽的工艺开发与生产能力为合作伙伴提供独特价值。另一方面,INNOVO平台未来主要聚焦在糖尿病、肥胖症、心血管疾病、非酒精性脂肪性肝炎、慢性肾病等重点疾病领域的创新发现,并寻找与蛋白质工程和制剂、寡核苷酸和干细胞治疗相关的创新平台与技术。



诺和诺德中国研发中心总裁苏京表示:“诺和诺德中国研发中心是跨国药企在中国建立的第一家生物医药研发机构,在药物研发领域拥有完善的科研能力,在早期药物靶标发现,验证,以及候选药物分子筛选等领域积累了丰富的经验。依托INNOVO开放创新平台,诺和诺德中国研发中心将作为创新加速器,构建学术界、医疗机构、生物制药公司、孵化器高效协作的创新网络,不断拓展药物研发的边界。希望能够通过该平台将诺和诺德中国研发中心打造成本地区的首选研发合作伙伴。”


苏京在回答记者提问时表示:INNOVO的合作伙伴包括三大类,侧重点也有所不同。与科研院所的合作更多是把科研成果转化成创新药物;跟初创公司合作则是一起全面推动项目向开发后期的成熟;跟孵化器类机构的合作更多是创新资源的集聚和增值。苏京同时透露了INNOVO开放创新平台的运营目标,希望在第一年接触洽谈100家合作伙伴,希望在未来3~5年输出3~5个项目,并且这些项目能够成熟到可以进一步国际化开发的阶段。


INNOVO对诺和诺德全球研发有何意义?


如果其他生物制药巨头的业务发展战略用“聚焦”来概括的话,诺和诺德就应该用“专注”来概括了。诺和诺德称得上是糖尿病领域的霸主,产品包括长效胰岛素、预混胰岛素、速效胰岛素、GLP-1等几大类。其他几款血友病和生长激素紊乱药品在诺和诺德整体收入中的占比相对较小。

 

诺和诺德全球研究技术部高级副总裁Lars Fogh Iversen在此次INNOVO平台启动仪式上表示诺和诺德在糖尿病领域仍有很多研发工作要做。他指出:全球约有4.25亿成人患糖尿病,只有非常小比例的患者的病情得到了有效控制。现在能够提供的治疗方式还是比较有限的,所以依然没有满足所有病人的需求,还有很大的提升空间。诺和诺德依然会去追求提升的机遇和增长空间,会继续对胰岛素进行研究。未来我们在糖尿病领域的研发重心是给2型糖尿病患者提供每周注射一次的胰岛素产品,以及血糖敏感胰岛素。胰岛素的研究依然是诺和诺德的研究核心。

在胰岛素之外,诺和诺德GLP-1药物还处于较稳定的高速增长状态。截至2018年11月,诺和诺德的胰岛素产品在全球胰岛素中的市场份额占到46.4%,同比增加了0.5个百分点。而GLP-1产品在全球糖尿病药物中的市场份额为14.5%,同比增加了2.7个百分点。特别是2017年进入国家医保目录后,利拉鲁肽在中国市场有比较明显的放量,2018年销售收入增长了73%,达到5.21亿丹麦克朗(约8250万美元),已经占到中国整个GLP-1药物87%的市场份额,占整个糖尿病药物市场1.3%的份额。此外,长效GLP-1受体激动剂索马鲁肽是诺和诺德的下一个王牌产品。诺和诺德还在针对1型糖尿病患者进行一些研究,比如尝试将免疫疗法、干细胞疗法用于1型糖尿病患者。

 

不过这家丹麦制药巨头的研发兴趣围绕糖尿病已经有了更多扩展。Marcus Schindler在接受记者采访时表示:诺和诺德除了继续专注于糖尿病的研究,现在对肥胖症、慢性肾病以及非酒精性肝炎等慢性病都有了越来越强烈的兴趣,并且持续加大了投入。所以我们需要更多的合作伙伴,希望他们能帮助我们进行新的化学物的发现,和我们一起努力推出更好的疗法。另外,我们对干细胞治疗这种新技术也是非常看好的,为此我们需要大量的专家支持,这也是我们启动INNOVO平台跟外部合作的原因。”

 

诺和诺德全球研究技术部高级副总裁Lars Fogh Iversen表示:“我们相信,建立长期可持续、合作共赢的生态体系会有效激发创新的活力。INNOVO开放创新平台的建立是诺和诺德合作创新(Partnering for Innovation)理念在中国的实践,也将为我们的全球研发战略转型提供更有力的支撑。”



正如诺和诺德全球高级副总裁兼大中国区总裁周霞萍在会上表示:“INNOVO开放创新平台的建立,是诺和诺德继续壮大创新生态系统的又一举措。在过去的25年中,诺和诺德一直致力于构建全方位、大格局的生态系统,携手合作伙伴,共同构筑抗击中国糖尿病的长城。未来,我们将紧密携手INNOVO的每一位合作伙伴,合力推动产品走向市场,让创意更快地达至患者,真正实现‘共创、共享、共赢’。”

机器翻译

On March 6, Novo Nordisk China R & D Center announced the launch of INNOVO Innovation Open Platform in Beijing, aiming at building a new ecology of R & D cooperation in pharmaceutical innovation and accelerating the transformation of scientific research results into innovative drug R & D through an open innovation cooperation model and joint efforts with China's local biomedical innovation force.

2019 marks the 25th anniversary of Novo Nordisk's business operation in China, when it chose to launch an open innovation platform, reflecting the upgrading of Novo Nordisk's innovation model and the importance it attaches to the Chinese market.Pharmcube was invited to the launch ceremony of the INNOVO Open Innovation Platform to share some information on the INNOVO platform's cooperative operation model and Novo Nordisk's global R & D strategy.

What is INNOVO?

With the deep implementation of the national "innovation-driven development" strategy and the continuous improvement of the innovation strength of the Chinese pharmaceutical industry, China has become one of the most active pharmaceutical markets in the world.On the policy level, the approval efficiency of Chinese drug regulatory agencies has increased significantly in recent years, and new drug investment has withdrawn.Medicare payment.The path of market access is also dredging, which has injected vitality into the development of the Chinese pharmaceutical industry.As a number of innovative drug companies began to enter the harvest period and innovative drugs were approved for marketing, more and more excellent entrepreneurs and start-ups are emerging.

China's "great" pharmaceutical industry has naturally attracted global attention, which can only be felt when Chinese companies have become the norm in cross-border cooperation in innovative drugs.As one of the established pharmaceutical giants that have been rooted in the Chinese market for many years, Novo Nordisk has established an R & D center in China earlier. This time, INNOVO initiated by Novo Nordisk China R & D Center is actually an open innovation and open platform, which is equivalent to Novo Nordisk's innovation in R & D mode. This marks that Novo Nordisk has been more focused on internal R & D since then and is willing to cooperate with the whole industry in a more open manner.

"Novo Nordisk's core contribution is to develop better medicines for patients who continue to innovate," Marcus Schindler, senior vice president of Global Drug Development at Novo Nordisk, said in an interview.We make long-term innovation investment in the search for the next generation of drugs, continuously improve the R & D capacity covering the complete value chain, and strengthen and supplement it through external cooperation to translate scientific ideas into tangible benefits for patients.We expect that INNOVO's open innovation model will be more effective in improving the efficiency of innovative drug development and meet the unmet medical needs of patients.

Marcus Schindler is also full of expectations for the operation of the INNOVO platform: "We must attract more external innovations from a global perspective, so that we can build very close partnerships with various partners, get good ideas and good technologies, and help us with scientific transformation.No matter where these ideas and technologies come from, we should consider working with them in depth, as long as they bring tangible benefits to patients.And we have accumulated a wealth of experience in selecting these ideas, and we can turn these ideas and technologies into products that can really benefit patients.Therefore, we believe that Novo Nordisk's INNOVO Open Innovation Platform will be the first platform for the company to truly cooperate systematically with external partners.On this platform we will invite a large number of scientists to join us.

What kind of partner does Novo Nordisk want?

In recent years, some pharmaceutical companies have actively explored and practiced open innovation.For example, Johnson & Johnson's JLABS, which settled in Zhangjiang in December 2017, replicates the operation model of its global open innovation platform and plans to accommodate nearly 50 innovative entities in the fields of life sciences and healthcare, attracting independent entrepreneurs or startup companies with which they are starting to work.Among domestic enterprises, the dream factory of Betta Pharmaceuticals can be said to be the same idea.

INNOVO has its own unique features.On the one hand, Novo Nordisk itself in diabetes.Hemophilia and other areas have a deeper accumulation, and is the first to establish R & D centers in China's multinational biopharmaceutical companies.In the operation of the INNOVO Open Innovation Platform, Novo Nordisk A/D China expects to rely on an in-depth understanding of the disease and patient situation.Strong preclinical and clinical experimental platform.The process development and production capacity of therapeutic proteins and peptides provide unique value to the partners.On the other hand, the INNOVO platform will focus on diabetes in the future.Obesity.Cardiovascular disease.Nonalcoholic steatohepatitis.Innovative discoveries in key disease areas such as chronic kidney disease and the search for protein engineering and agents.Innovative platforms and technologies related to oligonucleotide and stem cell therapy.

"Novo Nordisk China R & D Center is the first biomedical R & D institution established by a multinational drug company in China. It has sound scientific research capabilities in the field of drug R & D and has accumulated rich experience in early drug target discovery, validation, and molecular screening of drug candidates," said Su Jing, President of Novo Nordisk China R & D Center.Relying on INNOVO's open innovation platform, Novo Nordisk China R & D will act as an innovation accelerator to build academia.Medical institution.Biopharmaceutical companies.Incubators collaborate efficiently on innovative networks that continue to expand the boundaries of drug development.It is hoped that Novo Nordisk A/D China will be able to build the preferred R & D partner in the cost region through this platform.

In response to a reporter's question, Su Jing said: "INNOVO's partners include three broad categories, with different emphases."The cooperation with scientific research institutes is more about transforming scientific research results into innovative drugs.Working with startups is an overall push to mature projects into later stages of development.Cooperation with incubators is more about gathering and adding value to innovative resources.Su Jing also disclosed the operational objectives of INNOVO Open Innovation Platform, hoping to contact 100 partners in the first year and hope to export 3-5 projects in the next 3-5 years, and these projects can mature to the stage of further international development.

What does INNOVO mean for Novo Nordisk Global R & D?

If the business development strategies of other biopharmaceutical giants are summarized in "focus," Novo Nordisk should be summarized in "focus."Novo Nordisk is arguably the leading player in diabetes, with products including long-acting insulin.Premixed insulin.Faster acting insulin.GLP-1 and other major categories.Several other drugs for haemophilia and growth hormone disorders account for a relatively small proportion of Novo Nordisk's overall revenue.

Lars Fogh Iversen, Senior Vice President, Global Research Technologies, Novo Nordisk, told the INNOVO platform launch that Novo Nordisk still has a lot of R & D to do in diabetes.Diabetes affects some 425 million adults worldwide, and only a very small percentage of patients have their disease under control, he notes.There are still limited treatment options available, so there is still a lot of room for improvement.Novo Nordisk will continue to pursue opportunities for improvement and growth and will continue to study insulin.In the future, our research and development focus in the field of diabetes is to provide type 2 diabetes patients with weekly insulin injection products, as well as glucose-sensitive insulin.Insulin research remains central to Novo Nordisk's research.

In addition to insulin, Novo Nordisk's GLP-1 drugs are still in a steady state of rapid growth.As of November 2018, Novo Nordisk's insulin market share of global insulin accounted for 46.4 percent, an increase of 0.5 percent.The market share of GLP-1 products in diabetes drugs worldwide was 14.5%, an increase of 2.7 percentage points from the same period last year.Especially after entering the National Medical Insurance Catalogue in 2017, liraglutide has a relatively significant volume in the Chinese market. In 2018, sales revenue increased by 73% to 521 million DKK (about 82.5 million US dollars), which has accounted for 87% of the total market share of GLP-1 drugs in China and 1.3% of the total diabetes drug market.In addition, semaglutide, a long-acting GLP-1 receptor agonist, is Novo Nordisk's next brand.Novo Nordisk is also conducting studies in patients with type 1 diabetes, such as trying immunotherapy.Stem cell therapy for patients with type 1 diabetes.

But the Danish drug giant's interest in research and development has expanded more around diabetes.In addition to continuing to focus on diabetes research, Novo Nordisk is now focusing on obesity, Marcus Schindler said in an interview.Chronic diseases such as chronic kidney disease and non-alcoholic hepatitis are of increasing interest and continue to increase investment.So we need more partners who we hope will help us make new chemical discoveries and work with us to deliver better therapies.In addition, we are also very optimistic about the new technology of stem cell therapy, for which we need a lot of expert support, which is why we launched the INNOVO platform and external cooperation.

"We believe that building long-term sustainability.A win-win ecological system will be effective in stimulating innovation.The establishment of INNOVO Open Innovation Platform is the practice of Novo Nordisk's Partnership for Innovation in China, and will also provide stronger support for our global R & D strategy transformation.

As Zhou Xiaping, Novo Nordisk's global senior vice president and president of Greater China, said at the meeting: "The establishment of the INNOVO Open Innovation Platform is another initiative by Novo Nordisk to continue to expand its innovation ecosystem.Over the past 25 years, Novo Nordisk has been working on building omnidirectional.The great pattern of the ecosystem, together with partners, together to build the Great Wall of China to fight diabetes.In the future, we will work closely with each partner of INNOVO to push products to the market, so that ideas reach patients faster, and truly achieve 'co-creation.Share.Win-win '.

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号